This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsDelta 9 Cannabis (V5D1) 주식 개요는 자회사와 함께 통합 대마초 회사로 운영되고 있습니다. 자세히 보기V5D1 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장0/6과거 실적0/6재무 건전성2/6배당0/6강점공정 가치 추정치보다 낮은 97.9% 에서 거래위험 분석마이너스 주주 지분주식은 유동성이 매우 낮습니다지난 5년간 매년 수익이 51.6% 감소했습니다.지난 1년 동안 주주가 크게 희석되었습니다.+ 위험 1건 추가모든 위험 점검 보기V5D1 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.007295.8% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-26m177m2016201920222025202620282031Revenue CA$176.7mEarnings CA$26.0mAdvancedSet Fair ValueView all narrativesDelta 9 Cannabis Inc. 경쟁사BiofronteraSymbol: XTRA:B8FKMarket cap: €14.3mSynBioticSymbol: DUSE:SBXMarket cap: €7.6mCantourage GroupSymbol: XTRA:HIGHMarket cap: €76.8mRedx PharmaSymbol: DB:0RXMarket cap: €65.0m가격 이력 및 성과Delta 9 Cannabis 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$0.007252주 최고가US$0.07852주 최저가US$0.0062베타1.311개월 변동0%3개월 변동-2.70%1년 변동-80.75%3년 변동-97.37%5년 변동n/aIPO 이후 변동-99.70%최근 뉴스 및 업데이트공시 • Jul 16FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN).FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN) on July 15, 2024. MLT Aikins LLP acted as legal advisor to Delta 9 Cannabis Inc.Reported Earnings • May 17First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)First quarter 2024 results: CA$0.02 loss per share (in line with 1Q 2023). Revenue: CA$16.5m (down 2.4% from 1Q 2023). Net loss: CA$5.07m (loss widened 70% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany.공시 • Apr 20Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024.Reported Earnings • Apr 02Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)Full year 2023 results: CA$0.10 loss per share (improved from CA$0.22 loss in FY 2022). Revenue: CA$71.1m (up 12% from FY 2022). Net loss: CA$17.5m (loss narrowed 36% from FY 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.New Risk • Feb 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$606k). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (€3.09m market cap, or US$3.31m).공시 • Oct 31Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023Delta 9 Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023더 많은 업데이트 보기Recent updates공시 • Jul 16FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN).FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN) on July 15, 2024. MLT Aikins LLP acted as legal advisor to Delta 9 Cannabis Inc.Reported Earnings • May 17First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)First quarter 2024 results: CA$0.02 loss per share (in line with 1Q 2023). Revenue: CA$16.5m (down 2.4% from 1Q 2023). Net loss: CA$5.07m (loss widened 70% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany.공시 • Apr 20Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024.Reported Earnings • Apr 02Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)Full year 2023 results: CA$0.10 loss per share (improved from CA$0.22 loss in FY 2022). Revenue: CA$71.1m (up 12% from FY 2022). Net loss: CA$17.5m (loss narrowed 36% from FY 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.New Risk • Feb 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$606k). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (€3.09m market cap, or US$3.31m).공시 • Oct 31Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023Delta 9 Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023Reported Earnings • Aug 17Second quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2022)Second quarter 2023 results: CA$0.02 loss per share (improved from CA$0.04 loss in 2Q 2022). Revenue: CA$18.3m (up 4.3% from 2Q 2022). Net loss: CA$2.82m (loss narrowed 41% from 2Q 2022). Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.공시 • Jul 28Delta 9 Cannabis Inc. to Report Q2, 2023 Results on Aug 14, 2023Delta 9 Cannabis Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023New Risk • Jul 21New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €151k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.7m free cash flow). Shares are highly illiquid. Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (€6.62m market cap, or US$7.36m). Minor Risks Shareholders have been diluted in the past year (41% increase in shares outstanding). Significant insider selling over the past 3 months (€151k sold).공시 • May 09+ 1 more updateDelta 9 Cannabis Inc. to Report Q1, 2023 Results on May 15, 2023Delta 9 Cannabis Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 15, 2023공시 • Jan 19+ 1 more updateDelta 9 Cannabis Inc. to Report Q4, 2022 Results on Mar 31, 2023Delta 9 Cannabis Inc. announced that they will report Q4, 2022 results on Mar 31, 2023Reported Earnings • Nov 17Third quarter 2022 earnings released: CA$0.06 loss per share (vs CA$0.011 loss in 3Q 2021)Third quarter 2022 results: CA$0.06 loss per share (further deteriorated from CA$0.011 loss in 3Q 2021). Revenue: CA$15.7m (up 3.3% from 3Q 2021). Net loss: CA$7.40m (loss widened CA$6.28m from 3Q 2021). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jun 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 16First quarter 2022 earnings released: CA$0.04 loss per share (vs CA$0.042 loss in 1Q 2021)First quarter 2022 results: CA$0.04 loss per share (up from CA$0.042 loss in 1Q 2021). Revenue: CA$12.5m (down 5.7% from 1Q 2021). Net loss: CA$4.17m (loss narrowed 2.8% from 1Q 2021). Over the next year, revenue is forecast to grow 49%, compared to a 6.2% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.Board Change • May 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 04Full year 2021 earnings released: CA$0.11 loss per share (vs CA$0.072 loss in FY 2020)Full year 2021 results: CA$0.11 loss per share (down from CA$0.072 loss in FY 2020). Revenue: CA$62.3m (up 20% from FY 2020). Net loss: CA$11.2m (loss widened 74% from FY 2020). Over the next year, revenue is forecast to grow 24%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 31 percentage points per year, which is a significant difference in performance.Board Change • Apr 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Mar 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Dec 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • May 28Co-Founder recently sold €93k worth of stockOn the 26th of May, John Arbuthnot sold around 270k shares on-market at roughly €0.35 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by €121k.Recent Insider Transactions • May 22Co-Founder recently sold €78k worth of stockOn the 18th of May, John Arbuthnot sold around 230k shares on-market at roughly €0.34 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by €206k.Reported Earnings • May 18First quarter 2021 earnings released: EPS CA$0.04 (vs CA$0.023 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$13.2m (up 13% from 1Q 2020). Net loss: CA$4.29m (down 309% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 04Full year 2020 earnings released: CA$0.072 loss per share (vs CA$0.13 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CA$52.0m (up 64% from FY 2019). Net loss: CA$6.42m (down 159% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 29New 90-day low: €0.30The company is down 17% from its price of €0.37 on 30 October 2020. The German market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.16 per share.Recent Insider Transactions • Dec 24Co-Founder recently bought €62k worth of stockOn the 21st of December, John Arbuthnot bought around 176k shares on-market at roughly €0.35 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by €206k.Is New 90 Day High Low • Dec 22New 90-day low: €0.33The company is down 7.0% from its price of €0.36 on 22 September 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.37 per share.Reported Earnings • Nov 13Third quarter 2020 earnings released: CA$0.07 loss per shareThe company reported a mediocre third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: CA$13.1m (up 97% from 3Q 2019). Net loss: CA$5.85m (loss widened 307% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.공시 • Oct 14Delta 9 Cannabis Inc. Achieves Milestone in Agreement with Micro Cultivation PartnerDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Saskatchewan based Micro Cultivation partner, VIGR Life Cannabis Inc. (“VIGR”). As one of Delta 9’s Micro Cultivation partners, VIGR entered into a Strategic Cooperation Agreement (“SCA”) with the company whereby Delta 9 provides services relating to the cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, marketing services to develop the VIGR brand and other services supporting the acquisition of the Health Canada license. On October 2, 2020, VIGR confirmed it had reached its final milestone under the SCA and has been granted its cannabis micro cultivation licenses from Health Canada (the “Health Canada License”). VIGR has developed a micro cultivation facility, located in Regina, Saskatchewan. This new facility houses two adjacent micro cultivation licenses, including twenty-four new Grow Pod systems, and a proprietary craft growing approach developed by VIGR. VIGR expects this first facility to be the first step in a more significant growth plan, as it builds Saskatchewan’s leading craft cannabis company.공시 • Oct 01Delta 9 Cannabis Inc. to Report Q2, 2019 Results on Aug 27, 2019Delta 9 Cannabis Inc. announced that they will report Q2, 2019 results at 5:00 PM, Eastern Standard Time on Aug 27, 2019공시 • Sep 30Delta 9 Cannabis Inc. Achieves Milestone in Agreement with Micro Cultivation PartnerDELTA 9 CANNABIS INC. announced that it has completed its final services milestone under an agreement with another Micro Cultivation partner, Prairie Trichomes. Prairie Trichomes is an arms length third party in which the company has no ownership control or interest. As one of the company’s Micro Cultivation partners, Prairie Trichomes entered into a Strategic Cooperation Agreement with Delta 9 whereby Delta 9 provides services relating to the cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, and other services supporting the acquisition of the Health Canada license. On September 18, 2020, Prairie Trichomes confirmed it had reached its final milestone under the SCA and has been granted a cannabis micro cultivation license from Health Canada (the “Health Canada License”). The company's cannabis production methodology is based around a modular, scalable, and stackable production unit called a "Grow Pod", which are retrofitted standard 40-foot shipping containers. Prairie Trichomes’ facility has been designed and built using this turn key and Grow Pod system. Once cultivation begins, Delta 9 plans to purchase premium quality cannabis products from Prairie Trichomes for distribution through the Company's established distribution network, and through Delta 9's branded retail stores. Prairie Trichomes operates a 4th generation farm and has developed a 6,000 square foot micro cultivation facility, located in Carberry, Manitoba. The warehouse is only half utilized with the twelve new grow pods in place which provides room for expansion. The Carritt Family are experienced farmers who are excited to be a part of a new and growing industry. They became interested in growing cannabis to produce a premium cannabis crop year-round and provide additional jobs in rural Manitoba.공시 • Jul 31Delta 9 Cannabis Inc. to Report Q2, 2020 Results on Aug 14, 2020Delta 9 Cannabis Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 14, 2020공시 • Jun 16Delta 9 Cannabis Inc. (TSX:DN) entered into an agreement to acquire a 5% stake in Oceanic Releaf Inc. from Taylor Giovannini.Delta 9 Cannabis Inc. (TSX:DN) entered into a definitive agreement to acquire a 5% stake in Oceanic Releaf Inc. from Taylor Giovannini on June 15, 2020. As part of consideration, Oceanic will be paid by way of the provision of certain consulting and training services to Oceanic over a term of one year pursuant to a strategic cooperation agreement. The transaction is subject to obtaining of all required third party and governmental consents, authorizations and licenses required in connection therewith, including without limitation all required authorizations from Labrador Liquor Corporation.주주 수익률V5D1DE PharmaceuticalsDE 시장7D0%3.9%-0.9%1Y-80.7%29.3%1.9%전체 주주 수익률 보기수익률 대 산업: V5D1은 지난 1년 동안 29.3%의 수익을 기록한 German Pharmaceuticals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: V5D1은 지난 1년 동안 1.9%를 기록한 German 시장보다 저조한 성과를 냈습니다.주가 변동성Is V5D1's price volatile compared to industry and market?V5D1 volatilityV5D1 Average Weekly Movementn/aPharmaceuticals Industry Average Movement5.8%Market Average Movement5.8%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.8%안정적인 주가: V5D1의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine V5D1의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트2001320John Arbuthnotwww.delta9.ca는 자회사와 함께 통합 대마초 회사로 운영되고 있습니다. 이 회사는 의료용 및 기호용 대마초 제품의 재배, 가공, 추출, 도매 유통, 소매 및 판매에 종사하고 있습니다. 제품에는 말린 대마초 꽃, 프리롤, 말린 대마초 체, 오일, 추출 및 파생 제품이 포함됩니다.더 보기Delta 9 Cannabis Inc. 기초 지표 요약Delta 9 Cannabis의 순이익과 매출은 시가총액과 어떻게 비교됩니까?V5D1 기초 통계시가총액€2.50m순이익 (TTM)-€13.11m매출 (TTM)€47.25m0.1x주가매출비율(P/S)-0.2x주가수익비율(P/E)V5D1는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표V5D1 손익계산서 (TTM)매출CA$70.65m매출원가CA$58.10m총이익CA$12.55m기타 비용CA$32.15m순이익-CA$19.60m최근 보고된 실적Mar 31, 2024다음 실적 발표일해당 없음주당순이익(EPS)-0.054총이익률17.77%순이익률-27.74%부채/자본 비율-447.3%V5D1의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/09/03 10:11종가2024/07/16 00:00수익2024/03/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Delta 9 Cannabis Inc.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kimberly Thompson-HedlinCanaccord GenuitySiddharth RajeevFundamental Research Corp.Venkata VelagapudiResearch Capital Corporation
공시 • Jul 16FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN).FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN) on July 15, 2024. MLT Aikins LLP acted as legal advisor to Delta 9 Cannabis Inc.
Reported Earnings • May 17First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)First quarter 2024 results: CA$0.02 loss per share (in line with 1Q 2023). Revenue: CA$16.5m (down 2.4% from 1Q 2023). Net loss: CA$5.07m (loss widened 70% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany.
공시 • Apr 20Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024.
Reported Earnings • Apr 02Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)Full year 2023 results: CA$0.10 loss per share (improved from CA$0.22 loss in FY 2022). Revenue: CA$71.1m (up 12% from FY 2022). Net loss: CA$17.5m (loss narrowed 36% from FY 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
New Risk • Feb 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$606k). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (€3.09m market cap, or US$3.31m).
공시 • Oct 31Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023Delta 9 Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023
공시 • Jul 16FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN).FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN) on July 15, 2024. MLT Aikins LLP acted as legal advisor to Delta 9 Cannabis Inc.
Reported Earnings • May 17First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)First quarter 2024 results: CA$0.02 loss per share (in line with 1Q 2023). Revenue: CA$16.5m (down 2.4% from 1Q 2023). Net loss: CA$5.07m (loss widened 70% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany.
공시 • Apr 20Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024.
Reported Earnings • Apr 02Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)Full year 2023 results: CA$0.10 loss per share (improved from CA$0.22 loss in FY 2022). Revenue: CA$71.1m (up 12% from FY 2022). Net loss: CA$17.5m (loss narrowed 36% from FY 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
New Risk • Feb 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$606k). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (€3.09m market cap, or US$3.31m).
공시 • Oct 31Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023Delta 9 Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023
Reported Earnings • Aug 17Second quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2022)Second quarter 2023 results: CA$0.02 loss per share (improved from CA$0.04 loss in 2Q 2022). Revenue: CA$18.3m (up 4.3% from 2Q 2022). Net loss: CA$2.82m (loss narrowed 41% from 2Q 2022). Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.
공시 • Jul 28Delta 9 Cannabis Inc. to Report Q2, 2023 Results on Aug 14, 2023Delta 9 Cannabis Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023
New Risk • Jul 21New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €151k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.7m free cash flow). Shares are highly illiquid. Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (€6.62m market cap, or US$7.36m). Minor Risks Shareholders have been diluted in the past year (41% increase in shares outstanding). Significant insider selling over the past 3 months (€151k sold).
공시 • May 09+ 1 more updateDelta 9 Cannabis Inc. to Report Q1, 2023 Results on May 15, 2023Delta 9 Cannabis Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 15, 2023
공시 • Jan 19+ 1 more updateDelta 9 Cannabis Inc. to Report Q4, 2022 Results on Mar 31, 2023Delta 9 Cannabis Inc. announced that they will report Q4, 2022 results on Mar 31, 2023
Reported Earnings • Nov 17Third quarter 2022 earnings released: CA$0.06 loss per share (vs CA$0.011 loss in 3Q 2021)Third quarter 2022 results: CA$0.06 loss per share (further deteriorated from CA$0.011 loss in 3Q 2021). Revenue: CA$15.7m (up 3.3% from 3Q 2021). Net loss: CA$7.40m (loss widened CA$6.28m from 3Q 2021). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jun 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 16First quarter 2022 earnings released: CA$0.04 loss per share (vs CA$0.042 loss in 1Q 2021)First quarter 2022 results: CA$0.04 loss per share (up from CA$0.042 loss in 1Q 2021). Revenue: CA$12.5m (down 5.7% from 1Q 2021). Net loss: CA$4.17m (loss narrowed 2.8% from 1Q 2021). Over the next year, revenue is forecast to grow 49%, compared to a 6.2% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.
Board Change • May 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 04Full year 2021 earnings released: CA$0.11 loss per share (vs CA$0.072 loss in FY 2020)Full year 2021 results: CA$0.11 loss per share (down from CA$0.072 loss in FY 2020). Revenue: CA$62.3m (up 20% from FY 2020). Net loss: CA$11.2m (loss widened 74% from FY 2020). Over the next year, revenue is forecast to grow 24%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 31 percentage points per year, which is a significant difference in performance.
Board Change • Apr 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Mar 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Dec 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • May 28Co-Founder recently sold €93k worth of stockOn the 26th of May, John Arbuthnot sold around 270k shares on-market at roughly €0.35 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by €121k.
Recent Insider Transactions • May 22Co-Founder recently sold €78k worth of stockOn the 18th of May, John Arbuthnot sold around 230k shares on-market at roughly €0.34 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by €206k.
Reported Earnings • May 18First quarter 2021 earnings released: EPS CA$0.04 (vs CA$0.023 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$13.2m (up 13% from 1Q 2020). Net loss: CA$4.29m (down 309% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 04Full year 2020 earnings released: CA$0.072 loss per share (vs CA$0.13 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CA$52.0m (up 64% from FY 2019). Net loss: CA$6.42m (down 159% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 29New 90-day low: €0.30The company is down 17% from its price of €0.37 on 30 October 2020. The German market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.16 per share.
Recent Insider Transactions • Dec 24Co-Founder recently bought €62k worth of stockOn the 21st of December, John Arbuthnot bought around 176k shares on-market at roughly €0.35 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by €206k.
Is New 90 Day High Low • Dec 22New 90-day low: €0.33The company is down 7.0% from its price of €0.36 on 22 September 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.37 per share.
Reported Earnings • Nov 13Third quarter 2020 earnings released: CA$0.07 loss per shareThe company reported a mediocre third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: CA$13.1m (up 97% from 3Q 2019). Net loss: CA$5.85m (loss widened 307% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
공시 • Oct 14Delta 9 Cannabis Inc. Achieves Milestone in Agreement with Micro Cultivation PartnerDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Saskatchewan based Micro Cultivation partner, VIGR Life Cannabis Inc. (“VIGR”). As one of Delta 9’s Micro Cultivation partners, VIGR entered into a Strategic Cooperation Agreement (“SCA”) with the company whereby Delta 9 provides services relating to the cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, marketing services to develop the VIGR brand and other services supporting the acquisition of the Health Canada license. On October 2, 2020, VIGR confirmed it had reached its final milestone under the SCA and has been granted its cannabis micro cultivation licenses from Health Canada (the “Health Canada License”). VIGR has developed a micro cultivation facility, located in Regina, Saskatchewan. This new facility houses two adjacent micro cultivation licenses, including twenty-four new Grow Pod systems, and a proprietary craft growing approach developed by VIGR. VIGR expects this first facility to be the first step in a more significant growth plan, as it builds Saskatchewan’s leading craft cannabis company.
공시 • Oct 01Delta 9 Cannabis Inc. to Report Q2, 2019 Results on Aug 27, 2019Delta 9 Cannabis Inc. announced that they will report Q2, 2019 results at 5:00 PM, Eastern Standard Time on Aug 27, 2019
공시 • Sep 30Delta 9 Cannabis Inc. Achieves Milestone in Agreement with Micro Cultivation PartnerDELTA 9 CANNABIS INC. announced that it has completed its final services milestone under an agreement with another Micro Cultivation partner, Prairie Trichomes. Prairie Trichomes is an arms length third party in which the company has no ownership control or interest. As one of the company’s Micro Cultivation partners, Prairie Trichomes entered into a Strategic Cooperation Agreement with Delta 9 whereby Delta 9 provides services relating to the cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, and other services supporting the acquisition of the Health Canada license. On September 18, 2020, Prairie Trichomes confirmed it had reached its final milestone under the SCA and has been granted a cannabis micro cultivation license from Health Canada (the “Health Canada License”). The company's cannabis production methodology is based around a modular, scalable, and stackable production unit called a "Grow Pod", which are retrofitted standard 40-foot shipping containers. Prairie Trichomes’ facility has been designed and built using this turn key and Grow Pod system. Once cultivation begins, Delta 9 plans to purchase premium quality cannabis products from Prairie Trichomes for distribution through the Company's established distribution network, and through Delta 9's branded retail stores. Prairie Trichomes operates a 4th generation farm and has developed a 6,000 square foot micro cultivation facility, located in Carberry, Manitoba. The warehouse is only half utilized with the twelve new grow pods in place which provides room for expansion. The Carritt Family are experienced farmers who are excited to be a part of a new and growing industry. They became interested in growing cannabis to produce a premium cannabis crop year-round and provide additional jobs in rural Manitoba.
공시 • Jul 31Delta 9 Cannabis Inc. to Report Q2, 2020 Results on Aug 14, 2020Delta 9 Cannabis Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 14, 2020
공시 • Jun 16Delta 9 Cannabis Inc. (TSX:DN) entered into an agreement to acquire a 5% stake in Oceanic Releaf Inc. from Taylor Giovannini.Delta 9 Cannabis Inc. (TSX:DN) entered into a definitive agreement to acquire a 5% stake in Oceanic Releaf Inc. from Taylor Giovannini on June 15, 2020. As part of consideration, Oceanic will be paid by way of the provision of certain consulting and training services to Oceanic over a term of one year pursuant to a strategic cooperation agreement. The transaction is subject to obtaining of all required third party and governmental consents, authorizations and licenses required in connection therewith, including without limitation all required authorizations from Labrador Liquor Corporation.
